Literature DB >> 17534959

Levodopa responsiveness in disorders with parkinsonism: a review of the literature.

Radu Constantinescu1, Irene Richard, Roger Kurlan.   

Abstract

A literature review was conducted to investigate whether or not levodopa (LD) responsiveness (LR) is a useful criterion in the diagnosis of parkinsonian disorders. Although LR does appear to differ among the parkinsonian disorders, there is considerable confusion in the literature. While most patients with Parkinson's disease (PD) have a sustained benefit from LD, a small minority of patients with documented PD do not respond. The literature suggests that the LR rate is higher for multiple system atrophy (MSA), progressive supranuclear palsy (PSP), and corticobasal degeneration (CBD) than based on published diagnostic criteria. Magnitude and duration of response to LD and tolerability (time course, type and distribution of dyskinesias, mental effects and motor worsening) may be useful features in distinguishing PD, MSA, PSP, and CBD. Efforts should be directed toward better defining LR when used for diagnostic purposes and in scientific publications. (c) 2007 Movement Disorder Society.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17534959     DOI: 10.1002/mds.21578

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  23 in total

1.  Levels of HVA, 5-HIAA, and MHPG in the CSF of vascular parkinsonism compared to Parkinson's disease and controls.

Authors:  Megan K Herbert; H Bea Kuiperij; Bastiaan R Bloem; Marcel M Verbeek
Journal:  J Neurol       Date:  2013-12       Impact factor: 4.849

2.  How parkinsonism influences life: the patients' point of view.

Authors:  E Martignoni; Antonietta Citterio; R Zangaglia; L Godi; C Pacchetti; C Fundarò; E Corengia; G Bono; G Nappi
Journal:  Neurol Sci       Date:  2010-11-06       Impact factor: 3.307

Review 3.  The Differential Diagnosis and Treatment of Atypical Parkinsonism.

Authors:  Johannes Levin; Alexander Kurz; Thomas Arzberger; Armin Giese; Günter U Höglinger
Journal:  Dtsch Arztebl Int       Date:  2016-02-05       Impact factor: 5.594

4.  Multiple system atrophy: current and future approaches to management.

Authors:  Olivier Flabeau; Wassilios G Meissner; François Tison
Journal:  Ther Adv Neurol Disord       Date:  2010-07       Impact factor: 6.570

Review 5.  Functional neuroimaging in Parkinson's disease.

Authors:  Martin Niethammer; Andrew Feigin; David Eidelberg
Journal:  Cold Spring Harb Perspect Med       Date:  2012-05       Impact factor: 6.915

Review 6.  Dyskinesia in multiple system atrophy and progressive supranuclear palsy.

Authors:  Wolfgang H Jost; Paul Lingor; Lars Tönges; Johannes Schwarz; Carsten Buhmann; Jan Kassubek; Anette Schrag
Journal:  J Neural Transm (Vienna)       Date:  2019-05-13       Impact factor: 3.575

Review 7.  Current Treatment of Multiple System Atrophy.

Authors:  Sylvia Maaß; Johannes Levin; Günter Höglinger
Journal:  Curr Treat Options Neurol       Date:  2016-12       Impact factor: 3.598

8.  Differential diagnostic value of eye movement recording in PSP-parkinsonism, Richardson's syndrome, and idiopathic Parkinson's disease.

Authors:  Elmar H Pinkhardt; Reinhart Jürgens; Wolfgang Becker; Federica Valdarno; Albert C Ludolph; Jan Kassubek
Journal:  J Neurol       Date:  2009-01-14       Impact factor: 4.849

9.  Corticobasal degeneration.

Authors:  Stephen G Reich; Stephen E Grill
Journal:  Curr Treat Options Neurol       Date:  2009-05       Impact factor: 3.598

Review 10.  Manganism in the 21st century: the Hanninen lecture.

Authors:  Brad A Racette
Journal:  Neurotoxicology       Date:  2013-10-19       Impact factor: 4.294

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.